CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’
Company Faces Competition From J&J, Novavax
While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.
You may also be interested in...
Novartis Teams Up With CureVac To Make COVID-19 Vaccine
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
EMA Starts Rolling Review Of CureVac’s COVID-19 Vaccine
CureVac has submitted the pre-clinical data package for its COVID-19 vaccine to the European Medicines Agency, which will be reviewing the data on a rolling basis.